Northwest Biotherapeutics (LTS:0K95) Interest Expense : £-4.56 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Northwest Biotherapeutics's interest expense for the three months ended in Mar. 2024 was £ -1.20 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was £-4.56 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Northwest Biotherapeutics's Operating Income for the three months ended in Mar. 2024 was £ -12.39 Mil. Northwest Biotherapeutics's Interest Expense for the three months ended in Mar. 2024 was £ -1.20 Mil. Northwest Biotherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Northwest Biotherapeutics Interest Expense Historical Data

The historical data trend for Northwest Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Interest Expense Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.27

-6.36

-3.77

-4.98

-4.14

Northwest Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.85	-1.03	-1.35	-0.98	-1.20

Northwest Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-4.56 Mil.

Northwest Biotherapeutics (LTS:0K95) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Northwest Biotherapeutics's Interest Expense for the three months ended in Mar. 2024 was £-1.20 Mil. Its Operating Income for the three months ended in Mar. 2024 was £-12.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was £11.49 Mil.

Northwest Biotherapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Northwest Biotherapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Northwest Biotherapeutics (LTS:0K95) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NWBO:USA NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines